文献速递糖尿病

2型糖尿病合并慢性肾脏病患者中心血管和肾脏保护疗法的处方模式

Prescription Patterns of Cardiovascular- and Kidney-Protective Therapies Among Patients With Type 2 Diabetes and Chronic Kidney Disease.
PubMed 文献 · Diabetes Care · 2022-01-01

该横断面分析评估了2019年1月1日至2020年12月31日退伍军人健康管理系统中2型糖尿病患者的SGLT2i和GLP1-RA处方情况。在1,197,880名成人中,总体处方率分别为11%和8%,合并CKD者分别为12%和10%。合并严重白蛋白尿或高ASCVD风险的患者处方 odds 反而更低,呈现「风险-治疗悖论」。

要点

  • 在合并CKD的2型糖尿病患者中,SGLT2i和GLP1-RA的处方率分别仅为12%和10%。
  • 严重白蛋白尿患者相比无白蛋白尿的CKD患者,SGLT2i处方OR为0.91,GLP1-RA为0.97。
  • 10年ASCVD风险>20%者相比<5%者,SGLT2i处方OR为0.66,GLP1-RA为0.55。

核心结论

  • 在大量2型糖尿病患者中,合并CKD者的SGLT2i和GLP1-RA处方率低。
  • 观察到「风险-治疗悖论」,即不良结局风险较高的患者接受这些疗法的可能性反而较低。

研究设计与样本

  • 横断面分析,评估2019年1月1日至2020年12月31日退伍军人健康管理系统中SGLT2i和GLP1-RA的处方情况。
  • 共纳入1,197,880名2型糖尿病成人,按有无CKD以及预测的ASCVD和ESKD风险检查处方可能性。

主要发现

  • 总体中SGLT2i和GLP1-RA处方率分别为11%和8%;合并CKD者分别为12%和10%。
  • 严重白蛋白尿患者相比无白蛋白尿的CKD患者,SGLT2i处方OR为0.91(95%CI 0.89, 0.93),GLP1-RA处方OR为0.97(95%CI 0.94, 1.00)。
  • 10年ASCVD风险>20%者相比<5%者,SGLT2i处方OR为0.66(95%CI 0.61, 0.71),GLP1-RA处方OR为0.55(95%CI 0.52, 0.59)。
  • 5年ESKD风险>5%者相比<1%者,SGLT2i处方OR为0.63(95%CI 0.59, 0.67),GLP1-RA处方OR为1.53(95%CI 1.46, 1.61)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the prevalence and correlates of prescription of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and/or glucagon-like peptide 1 receptor agonists (GLP1-RA) in individuals with type 2 diabetes mellitus (T2DM) with and without chronic kidney disease (CKD). RESEARCH DESIGN AND METHODS: This was a cross-sectional analyses of SGLT2i and GLP1-RA prescriptions from 1 January 2019 to 31 December 2020 in the Veterans Health Administration System. The likelihood of prescriptions was examined by the presence or absence of CKD and by predicted risks of atherosclerotic cardiovascular disease (ASCVD) and end-stage kidney disease (ESKD). RESULTS: Of 1,197,880 adults with T2DM, SGLT2i and GLP1-RA were prescribed to 11% and 8% of patients overall, and to 12% and 10% of those with concomitant CKD, respectively. In adjusted models, patients with severe albuminuria were less likely to be prescribed SGLT2i or GLP1-RA versus nonalbuminuric patients with CKD, with odds ratios (ORs) of 0.91 (95% CI 0.89, 0.93) and 0.97 (0.94, 1.00), respectively. Patients with a 10-year ASCVD risk >20% (vs. <5%), had lower odds of SGLT2i use (OR 0.66 [0.61, 0.71]) and GLP1-RA prescription (OR 0.55 [0.52, 0.59]). A 5-year ESKD risk >5%, compared with <1%, was associated with lower likelihood of SGLT2i prescription (OR 0.63 [0.59, 0.67]) but higher likelihood of GLP1-RA prescription (OR 1.53 [1.46, 1.61]). CONCLUSIONS: Among a large cohort of patients with T2DM, prescription of SGLT2i and GLP1-RA was low in those with CKD. We observed a "risk-treatment paradox," whereby patients with higher risk of adverse outcomes were less likely to receive these therapies.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Lamprea-Montealegre JA, Madden E, Tummalapalli SL, et al. Prescription Patterns of Cardiovascular- and Kidney-Protective Therapies Among Patients With Type 2 Diabetes and Chronic Kidney Disease. Diabetes Care. 2022. PMID: 36156061. doi:10.2337/dc22-0614

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。